Ginkgo Bioworks to discover and develop novel vaccine adjuvants
A five-year contract totalling up to $31 million including programme options has been awarded to Ginkgo Bioworks to discover and develop next-generation vaccine adjuvants. The contract was awarded by the Defense Threat Reduction Agency’s (DTRA) Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense (CBD)… Read More